DEMECAN expands and diversifies its network of international suppliers of cannabis

Berlin/Dresden, June 09, 2022 – DEMECAN has signed major supply agreements for medicinal cannabis flowers with Little Green Pharma (Denmark), Safricanna (South Africa), and Atlas Growers (Canada). Over the next few years, DEMECAN will be supplied exclusively with at least 6 different medical cannabis flowers from these three suppliers. Deliveries will begin this year, subject to regulatory and licensing requirements. The combined amount will be over 2.2 tons of dried cannabis flower in the first year of delivery alone.

DEMECAN is Germany’s leading medical cannabis company and the only independent German company to have been awarded the contract by the Federal Institute for Drugs and Medical Devices (BfArM) to grow, process and distribute medical cannabis in Germany. In April, DEMECAN delivered for the first time from its domestically cultivated cannabis flowers directly to the BfArM. To guarantee the security of supply for patients in Germany, DEMECAN also works as a pharmaceutical wholesaler with cannabis producers worldwide and imports medical cannabis.

By expanding its supplier network, DEMECAN will continue to lead the way in providing patients with the highest quality medical cannabis products and at the same time diversifies its supplier network for the upcoming legalization of recreational cannabis in Germany. This allows DEMECAN to further consolidate its position as the go-to company for medical cannabis and at the same time provides a possible advantage for the future recreational cannabis market in Germany.


DEMECAN is the only independent German company that covers the entire value chain for medical cannabis - from cultivation to processing and storage to distribution to pharmacies. The company was founded in 2017 by Dr. Adrian Fischer, Dr. Cornelius Maurer and Dr. Constantin von der Groeben with the aim of guaranteeing patients access to medical cannabis in "Made in Germany" quality. In May 2019, DEMECAN was awarded a state contract by the Federal Institute for Drugs and Medical Devices (BfArM) as the only independent German company to cultivate medical cannabis in Germany. Cultivation and further processing are carried out according to the highest pharmaceutical standards (EU-GMP) at the company's facility near Dresden. As a pharmaceutical wholesaler, DEMECAN works with cannabis producers worldwide and imports medical cannabis that meets its own high-quality standards. The DEMECAN Group is a member of the Federal Association of Pharmaceutical Cannabinoid Companies (BPC) and a supporting member of the Association of Pharmacies Supplying Cannabis (VCA e.V.).

Further Information:
Press contact:

Weitere Presse­mitteilungen